Veradermics (MANE) Liabilities and Shareholders Equity (2024 - 2026)

Veradermics (MANE) has 3 years of Liabilities and Shareholders Equity data on file, last reported at $397.4 million in Q1 2026.

• For the quarter ending Q1 2026, Liabilities and Shareholders Equity changed N/A year-over-year to $397.4 million; the trailing twelve-month figure through Mar 2026 stood at $605.5 million (changed N/A YoY), and the FY2025 full-year result was $152.6 million, up 174.82% from the prior year.
• Liabilities and Shareholders Equity for Q1 2026 stood at $397.4 million, up from $152.6 million in the prior quarter.
• Across five years, Liabilities and Shareholders Equity topped out at $397.4 million in Q1 2026 and bottomed at $55.5 million in Q4 2024.
• The 3-year median for Liabilities and Shareholders Equity is $152.6 million (2025), against an average of $201.8 million.
• Peak annual rise in Liabilities and Shareholders Equity reached 174.82% in 2025, while the deepest fall reached 174.82% in 2025.
• A 3-year view of Liabilities and Shareholders Equity shows it stood at $55.5 million in 2024, then jumped by 174.82% to $152.6 million in 2025, then surged by 160.36% to $397.4 million in 2026.
• The last three Liabilities and Shareholders Equity figures came in at $397.4 million (Q1 2026), $152.6 million (Q4 2025), and $55.5 million (Q4 2024), per Business Quant data.

Peer Comparison